Biotech Values

[DewDiligence]

Late-Stage Drug Candidates Looking for a Home

Criteria for inclusion:
a) Program has completed phase-2b or later and is non-partnered; AND
b) Company lacks the financial resources to commercialize the product on its own.


Edits: Added AIS’ Anturol.

  
 Company  Product     Phase   Indication (notes) 
 =======  =======     =====   ================== 
 AIS      Anturol     NDA     OAB (gel formulation of oxybutynin) 
 ARYX     Budiodarone 2b      Atrial Fibrillation           
 ARYX     Tecarfarin  3       VTE prevention (failed initial ph-3)                  
 BPAX     Libigel     3       Female Sexual Desire Disorder        
 ONCY     Reolysin    3       SCC Head & Neck cancer (ph-3 SPA)  
 OXGN     Zybrestat   3       Anaplastic thyroid cancer             
 MNKD     Afrezza     BLA     Diabetes (CRL rec’d 3/15/10)             
 Pharming Rhucin      BLA     HAE (approved in EU; US BLA by end 2010)             
 SVNT     Krystexxa   BLA     Gout (response to CRL submtd 3/30/10)             
 VVUS     Qnexa       NDA     Obesity

Procedure for Updating Table

1. Copy the text in this post into a word processor.

2. Using a monospace font (e.g. Courier) to facilitate tabular
alignment, make your additions and modifications, inserting
them in the table in alphabetical order. NOTE: use spaces
rather than tab characters.

3. Add a brief note in the “Edits:” line atop the table to
describe your changes.

4. Insert the iHub formatting directives: Put [ pre ] at the
beginning of the table without the surrounding spaces, and
put [ /pre ] at the end of the table without the surrounding
spaces.

5. Post your text as a reply to this message.

Thank you for your cooperation.